ArticleIranian journal of basic medical sciences2026
Role of gallic acid in sarcopenia in D-galactose-treated mice.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Aging is a natural phenomenon that results in sarcopenia to impair living quality in humans. Gallic Acid (GA) has many biological activities against aging and muscle injury. Our purpose was to clarify possible mechanisms of GA on aged-relevant sarcopenia. Materials and Methods: Senescent model was established by D-galactose in mice. The senescent model was treated with GA for 10 weeks. Skeletal muscle was stained via HE to assess muscle fiber size. Oxidation indicators and inflammatory factors were detected using a spectrophotometer and ELISA. The protein expressions were tested by Western blot. Results: Our data unveiled GA enhanced muscle mass to improve grip strength and fatigue in D-galactose-induced aging mice. In serum, GA increased T-AOC, SOD and CAT levels, and decreased MDA, TNF-α, and IL-6 levels to exert its anti-oxidative and anti-inflammatory properties. In skeletal muscle, GA decreased atrogin 1, Murf-1, collagen I, and Tgf-β1 expressions to improve atrophy and fibrosis. Furthermore, GA increased Pgc-1α, Nrf-1, Beclin-1, and Bcl-2 expressions, and decreased P62 and Bax expressions to prevent skeletal muscle damage. Conclusion: GA exerted its protective effects on sarcopenia concomitant aging via moderating mitochondrial biology, enhancing autophagy and restraining apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.